Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 10/20 | 0.47 |
| ▸ | GPR55 | Q9Y2T6 | 9/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12377820 | 0.74 | NOTUM (0.55) | NOTUMNPC1RAB9AHPGDTSHR | |
| SCHEMBL12377824 | 0.73 | NOTUM (0.47) | NOTUMNPC1RAB9AHPGDTSHR | |
| SCHEMBL12377823 | 0.70 | NOTUM (0.49) | NOTUMNPC1RAB9AHPGDTSHR | |
| SCHEMBL12377822 | 0.70 | IL2 (0.49) | NOTUMNPC1RAB9AHPGDTSHR | |
| SCHEMBL12377837 | 0.70 | RAB9A (0.58) | NPC1RAB9ASMN1; SMN2TP53MAPT | |
| SCHEMBL6240111 | 0.69 | CNR1 (0.56) | CNR1GPR55CNR2HPGDSMN1; SMN2 | |
| SCHEMBL12377825 | 0.68 | GRIN1 (0.47) | NOTUMNPC1RAB9AHPGDTSHR | |
| SCHEMBL12377829 | 0.68 | GRIN1 (0.47) | NOTUMNPC1RAB9AHPGDTSHR | |
| SCHEMBL12377830 | 0.67 | NOTUM (0.45) | NOTUMNPC1RAB9AHPGDTSHR | |
| SCHEMBL12377833 | 0.67 | GAA (0.47) | NOTUMNPC1RAB9AHPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998954-B2 | Pyrimidodiazepinone derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-7998954-B2 | Pyrimidodiazepinone derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20100190775-A1 | PYRIMIDODIAZEPINONE DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190775-A1 | PYRIMIDODIAZEPINONE DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD (JP) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190775-A1 | PYRIMIDODIAZEPINONE DERIVATIVE | KCNJ1, KCNJ11, ADRA1D | CNR1 91/4885GPR55 1005/4885CNR2 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.